

This material may be protected by Copyright law (Title 17 U.S. Code)

Neurogenic inflammation in the pathophysiology and treatment of migraine

Michael A. Moskowitz, MD

Article abstract—The trigeminal nerve transmits headache pain from blood vessels of the pia mater and dura mater. Triggers for this pain are not well understood, but probably are multiple and largely chemical and develop within the brain parenchyma, the blood vessel wall, and the blood itself. These unknown triggers stimulate the trigeminovascular axons, causing pain and releasing vasoactive neuropeptides from perivascular axons. Released neuropeptides activate endothelial cells, mast cells, and platelets to then increase extracellular levels of amines, arachidonate metabolites, peptides, and ions. Hyperalgesia and prolongation of pain develop as a consequence, mediated by products from activated cells and injured tissue. Within postsynaptic brain stem neurons of the trigeminal nucleus caudalis, trigeminovascular activation stimulates the expression of an early immediate response gene *c-fos*. Both neurogenic inflammation and *c-fos* expression are blocked by sumatriptan and ergot alkaloids via prejunctional mechanisms involving putative 5-HT receptors closely related to the 5-HT_{1D} subtype on trigeminovascular fibers. The mechanisms of action of sumatriptan and ergot alkaloids described herein are unrelated to the nature of the migraine trigger or to the contractile state of vascular smooth muscle.

NEUROLOGY 1993;43(suppl 3):S16-S20

Neurogenic inflammation within cephalic tissue, involving vasodilation and plasma protein extravasation, has been proposed as a mechanism in headache pathogenesis.¹⁻⁴ This article is a review of the roles of neurogenic inflammation and prejunctional mechanisms in headache pathogenesis and the treatment of vascular headache.

Pathophysiology. Neurogenic inflammation is mediated by the release of the vasoactive neuropeptides substance P,⁵ neurokinin A, and calcitonin gene-related peptide (CGRP) from sensory fibers that innervate blood vessels.^{6,7} Both the endothelium-dependent vasodilation and the enhanced permeability induced by the tachykinins are mediated by receptors located on the vascular endothelium; dilation produced by CGRP is mediated by receptors on vascular smooth muscle.⁸

Neurogenic plasma protein extravasation. During electrical trigeminal ganglia stimulation or after IV administration of capsaicin, neurogenic plasma protein extravasation develops within the dura mater.⁹ This tissue, an important source of headache pain,¹⁰ provides a thick covering for the brain and contains blood vessels with fenestrated capillary endothelia.¹¹ The dura mater and its attendant blood vessels are innervated by neuropeptide-containing trigeminal and upper cervical sensory nerve fibers,^{12,13} perivascular sensory

axons, located within the adventitial layer, are unmyelinated and small.

When plasma proteins, such as iodinated albumin or horseradish peroxidase, are administered, leakage from vessels into surrounding tissue can be demonstrated after trigeminal nerve stimulation. This extravasation is markedly attenuated or absent in animals whose perivascular afferent fibers have been destroyed by capsaicin treatment during the neonatal period. In comparison, the systemic administration of substance P or neurokinin A produces the same amount of leakage from dural vessels as do vehicle-treated, electrically stimulated controls. Plasma proteins do not extravasate from the pial circulation under the same conditions, probably because of the blood-brain barrier.

Trigeminal ganglia and electrical stimulation. Recent light and electron microscopy studies have shown that following electrical trigeminal ganglion stimulation, striking changes occur in the appearance of endothelial and mast cells as well as in the platelets surrounding or within postcapillary venules.¹⁴ Platelet aggregates appeared within the lumen on the stimulated side only shortly after stimulation; some were found adhering to the endothelium. Endothelial cells later developed numerous clear cytoplasmic vesicles and vacuoles; the endothelium hypertrophied and microvilli formed. Mast cells also showed signs of secretion

From the Stroke Research Laboratory, Neurosurgery and Neurology Services, Massachusetts General Hospital, Harvard Medical School, Boston.

Address correspondence and reprint requests to Dr. Michael A. Moskowitz, Department of Neurology, Massachusetts General Hospital, 32 Fruit Street, Boston, MA 02114.

degranulation as seen in the loss of normal functional properties, ultrastructural disintegration of plasma membrane, and loss of electron-dense material within cytoplasmic granules. Following a 5-minute stimulation period, frank degranulation became evident 20 minutes later. All of these changes depended on the presence of small, unmyelinated fibers and were not noted after ganglionic stimulation in animals treated with capsaicin as neonates.

Sensitization and hyperalgesia. In migraine, noxious triggers, which remain to be identified, initiate a complex cascade of events within the meninges that cause both pain through depolarization of primary afferents and long-lasting enhancement of nociceptor activity that leads to sensitization and hyperalgesia.^{3,15,16} Neither event, of course, is unique to the meninges or to migraine, and both occur within the skin, joints, and eye, as well as in the urinary and respiratory tracts.¹⁷⁻¹⁹ Important chemical mediators that modulate sensory transduction in affected tissue include potassium, serotonin (5-HT), bradykinin, histamine, prostaglandins, leukotrienes, substance P, and CGRP.²⁰ In injured tissue—or tissue threatened with injury—the extracellular concentrations of these chemicals increase by release from local cells (potassium, histamine, 5-HT), local synthesis (prostaglandins, leukotrienes, bradykinin), or release from sensory axons (neuropeptides). Hyperalgesia and pain occur as a consequence of the initial trigger and the cellular response to neurogenic inflammation.

Blocking neurogenic plasma protein extravasation. Pharmacologic observations that 5-HT₁ agonists with some selectivity for the D-type receptor block inflammation selectively within the dura mater, support the belief that neurogenic inflammation is especially relevant to vascular headache.^{15,21} Vasoconstriction mediated by 5-HT_{1D} receptors on vascular smooth muscle plays a minor role, if any.

Response to sumatriptan and related compounds. Studies have shown that neurogenic plasma protein extravasation from blood vessels in the dura mater can be significantly reduced by drugs such as sumatriptan, 5-carboxamidotryptamine (5-CT), dihydroergotamine (DHE), ergotamine tartrate, and methysergide. The dosage of sumatriptan required to block extravasation is similar to that required to treat acute migraine in humans.^{15,22}

The response to these agents has been most consistent with an effect mediated by 5-HT_{1D} receptors or analogous 5-HT_{1B} receptors in rats. Some notable exceptions were found, however. Pretreatment with the 5-HT₁ antagonist metergoline only partially reversed the response to sumatriptan, and methiothepine did not reverse the response at all. The effect of 5-CT was not blocked by either antagonist, and serotonin itself appears inactive in this model. Pretreatment with 5-HT

antagonists (pizotifen, ketanserin) or 5-HT₃ antagonists (MDL 7222, ICS 205-930) did not affect leakage, which is consistent with a 5-HT₁ receptor-mediated response.

However, the rank order of effective dosages, or threshold concentrations of 5-HT_{1D} selective compounds, does not correlate with affinities for the same drugs at the 5-HT_{1D} receptor binding site determined by ligand binding in vitro. Hence, emerging pharmacology suggests that a receptor subtype other than 5-HT_{1D} may mediate the antineurogenic inflammatory effects of sumatriptan and DHE. This receptor is present only in intracranial tissue innervated by the trigeminal nerve; the equivalent or higher concentrations of sumatriptan or ergot alkaloid do not block plasma protein extravasation in extracranial cephalic tissue.

Prejunctional mechanisms and inhibited neuropeptide release. Several lines of evidence support the conclusion that 5-HT heteroreceptors are located on neuropeptide-containing unmyelinated C fibers. Prejunctional mechanisms and inhibited neuropeptide release mediate drug blockade of plasma leakage within the dura mater. First, sumatriptan and DHE are inactive when tested against concentrations of substance P or neurokinin A, which cause plasma leakage. Later experiments have found sumatriptan, also, to be inactive against leakage caused by α -methyl 5-HT, a 5-HT₂ agonist that stimulated endothelial cell leakage directly. Extravasation caused by α -methyl 5-HT was blocked by pretreatment with the 5-HT₂ antagonist pimozone. Second, DHE and, to a lesser extent, sumatriptan attenuated the increase in immunoreactive CGRP within sagittal sinus blood (venous effluent) during electrical stimulation of the trigeminal ganglion.²³ This presumably reflects the inhibition of neuropeptide release. Third, sumatriptan and DHE pretreatment block platelet aggregation, endothelial vesicle formation within postcapillary venules, mast cell secretion, and degranulation in the dura mater.²⁴

These findings are difficult to reconcile with a mechanism based on activation of postjunctional receptors on vascular smooth muscle, endothelial cells, or sympathetic fibers. Sympathetic fibers were in fact ruled out as a possible mediator by direct experiments showing that sumatriptan inhibits neurogenic plasma extravasation in sympathectomized animals.

Recently, in situ hybridization studies have demonstrated that the 5-HT_{1D/B} gene is expressed within trigeminal ganglia.²⁵ Moreover, the expressed gene has been amplified using the polymerase chain reaction and oligonucleotide probes complementary to the cDNA prepared from the 5-HT_{1D} receptor message (unpublished data).

Role of 5-HT₁ receptors. Studies involving sumatriptan and endopeptidase 24.11 (enkephalinase), an enzyme that degrades substance P and CGRP, suggest a coupling between the 5-HT receptor and

and dura mater. develop within the trigeminovascular peptides activate late metabolites, products from actinidalis, trigeminogenic inflammatory systems of action of or to the contrac-

suppl 3):S16-S20

tial layer, are

iodinated albumin administered, ing tissue can be ve stimulation. attenuated or ular afferent aicin treatment arison, the sys- ? or neurokinin cage from dural ically stimulat- not extravasate ne same condi- brain barrier.

al stimulation. py studies have eminal ganglion in the appear- is well as in the postcapillary ve- red within the y shortly after dhering to the ater developed s and vacuoles; and microvilli gns of secretion

School, Boston. pital, 32 Fruit Street,

the blockade of neuropeptide release. When administered after stimulation, the two agents were found to exhibit nearly identical time-dependent effects. They blocked plasma extravasation, even when administered 60 minutes after the 5-minute stimulation period. After terminating the stimulus in our model, neuropeptide release from sensory fibers appeared to continue for some time. Blockade of neuropeptide release from sensory fibers was consistent with the role of 5-HT_{1D} receptors as inhibitors of presynaptic neurotransmitter release within brain and perivascular sympathetic nerve fibers.²⁴⁻²⁶ More recent data indicate that α_2 , H₃, μ -opioid, and somatostatin receptors may also be located on trigeminovascular fibers and may block neurogenic plasma extravasation.²⁷

C-fos expression. C-fos protein, a nuclear phosphoprotein that regulates the transcription rate of target genes, may play a role in the long-term alteration of cellular function.²⁸⁻³¹ This phosphoprotein can be induced in neurons in the dorsal horn of the spinal cord by noxious and non-noxious stimuli.³²⁻³⁴ Noxious stimuli increase the number of cells expressing c-fos protein within Rexed's laminae (I and II_o), where unmyelinated C fibers terminate and spinothalamic projecting neurons predominate.³⁴⁻³⁶

Continuous or prolonged stimulation evokes the most robust response, and the number of cells containing c-fos protein correlates with stimulus intensity. In the same way, the number of positive cells decreases after analgesic administration. For example, the number of positive cells in the dorsal horn has been correlated with the nociceptive behavioral response observed in rats after formalin has been injected into the hind paw. In the formalin experiments, the number of expressing cells decreased after morphine administration in a dose-dependent, naloxone-sensitive manner.^{35,36} C-fos expression provides both spatial and temporal markers of neuronal activation following sensory stimulation.

The trigeminal nucleus caudalis. We have recently studied c-fos expression within the trigeminal nucleus caudalis after instilling autologous blood into the subarachnoid space of rats.³⁷ The trigeminal nucleus caudalis receives the major synaptic input from the trigeminal nerve and contains neurons that discharge when the meninges are stimulated.³⁸

When placed in the subarachnoid space, blood is noxious, as evidenced by the development of severe headache, nausea and vomiting, photophobia, and vasoconstriction in humans. In our model, the injection of blood increased the number of cells expressing the c-fos protein within laminae I and II_o. The number of expressing cells corresponded to the amount of blood injected, and the number of responding cells was maximal 2 hours after injection. After surgical or chemical denervation, the number of expressing cells was reduced by 50% or

more. In our model, inhibition of c-fos expression was probably also related to the development of analgesia because pretreatment with morphine decreased the number of expressing cells.

Pretreatment with 5-HT₁ agonists with some selectivity for the B- and D-subtype receptors (and morphine) reduced the number of c-fos-positive cells caused by instilling blood. CP-93 129,^{39,40} a selective 5-HT_{1B} agonist, sumatriptan, or dihydroergotamine decreased the number of positive cells significantly in laminae I and II_o, compared with those in vehicle-treated animals.⁴¹ Sumatriptan did not block c-fos expression in the trigeminal nucleus caudalis following formalin application to the nasal mucosa. This means that sumatriptan is fundamentally different from such analgesics as morphine.

Inhibiting c-fos expression. Drug-induced blockade of c-fos expression may well be mediated by receptors on primary afferent (trigeminovascular) fibers. Consistent with this conclusion, we found that chemical or surgical denervation, as well as drugs such as CP-93 129, sumatriptan, and DHE, caused a similar pattern of c-fos inhibition within the brain stem. This was seen in the reduced number of expressing cells in the caudalis but not in the nucleus of the solitary tract or area postrema.^{40,41} Administering CP-93 129 did not decrease the number of expressing cells below the 50% inhibition in chemically denervated animals, suggesting the importance of extracerebral sites to drug activity.

If the inhibition of c-fos expression within laminae I and II_o correlates with the amelioration of pain, we can infer that constricted blood vessels are not required to alleviate pain by sumatriptan and DHE and, furthermore, that dilation may not be the pain stimulus, or trigger, in vascular headaches. Blood vessel constriction, which occurs after blood enters the subarachnoid space, provides further evidence that 5-HT_{1D}-receptor-mediated vasoconstriction may not be necessary for therapeutic effect.

We recently demonstrated that recurrent spreading depression induces c-fos expression within lamina I, II_o trigeminal nucleus caudalis, as does the intracisternal administration of carageenan, a proinflammatory agent.⁴² C-fos expression following spreading depression (SD) was also blocked by prior sectioning of trigeminal meningeal afferents. Sumatriptan did not affect the ability of the brain tissue to initiate and/or propagate SD.⁴³ Quite remarkably, sumatriptan suppressed c-fos expression in both instances, raising the possibility that 5-HT_{1D} agonists may alleviate pain associated with a wide variety of conditions, including bacterial and viral meningitis and head injury.

Based on the results of these experiments, we suggest that under certain circumstances (eg, migraine), the cortical mantle releases nociceptive molecules and generates the pain signal of the migraine. The released molecules collect in the

extracellular and innervated draining activation of trigeminal ganglion for the decade of physiological and anticipate and prov

Conclusion. Our that the actions of connected to at least diminish pain and vascular headache neural transmiss fibers and, by so postsynaptic brain they block the neu ing afferent fiber applications of these associated with me consideration.

The occurrence of nal nucleus caud depression suggest vide a potential s graine.

For more detail cussed in this arti the original rese years.^{1-3,12-16,21-24,37,38}

References

1. Moskowitz MA, R rotransmitters and to the headache 1 885.
2. Mayberg M, Lang meningeal projecti pathway for vas 213:228-230.
3. Moskowitz MA. Th Neurol 1984;16:157.
4. Hardebo JE. The neurons in cluste 1984;24:294-304.
5. Lembeck F, Holze of antidromic vasc sation. Naunyn 310:175-183.
6. Saria A, Gamse tachykinins and c nerves in relation R, Sunder F, ed Elsevier Science P
7. Saria A, Gamse R, of several tachyki from rat spinal cor
8. Brain SD, Williar related peptide is 56.
9. Markowitz S, Sait ated leakage of pl dura mater but no
10. Ray BS, Wolff HG sensitive structu headache. Arch St
11. Andres KH, von I and their termin

-fos expression development of with morphine cells.

receptors (and c-fos-positive P-93 129, 39, 40) a an, or dihydro- of positive cells compared with umatriptan did eminal nucleus ion to the nasal ptan is funda- gesics as mor-

-induced block- be mediated by eminovascular) sion, we found ion, as well as ptan, and DHE inhibition within e reduced num- is but not in the a postrema. 40, 41 decrease the the 50% inhibi- als, suggesting s to drug activi-

on within lami- amelioration of blood vessels are umatriptan and ion may not be vascular head- ouch occurs after ce, provides fur- mediated vaso- for therapeutic

hat recurrent expression with- us caudalis, as tration of car- t. 42 C-fos expres- n (SD) was also ninal meningeal ect the ability of propagate SD. 41 uppressed c-fos g the possibility pain associated ncluding bacteri- jury.

experiments, we instances (eg, mi- ases nociceptive pain signal of collect in the

extracellular and perivascular space and within innervated draining veins leading to discharge and activation of trigeminovascular fibers. The challenge for the decade ahead is to identify those neurophysiological and metabolic brain events which anticipate and provoke the pain of migraine.

Conclusion. Our data support the formulation that the actions of sumatriptan and DHE are connected to at least two important events that may diminish pain and sensitization in patients with vascular headache. Sumatriptan and DHE block neuronal transmission within trigeminovascular fibers and, by so doing, gene expression within postsynaptic brain stem neurons. At the same time, they block the neuroinflammatory response following afferent fiber stimulation. The therapeutic applications of these compounds to other conditions associated with meningeal irritation merit further consideration.

The occurrence of c-fos within ipsilateral trigeminal nucleus caudalis after recurrent spreading depression suggests that the brain can indeed provide a potential source for the pain signal of migraine.

For more detailed descriptions of the work discussed in this article, we encourage examination of the original research published in the past 10 years. 1-3, 12-16, 21-24, 37, 38, 40, 41, 43

References

1. Moskowitz MA, Reinhard JF Jr, Romero J, et al. Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? *Lancet* 1979;2:883-885.
2. Mayberg M, Langer RS, Zervas NT, et al. Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. *Science* 1981; 213:228-230.
3. Moskowitz MA. The neurobiology of vascular head pain. *Ann Neurol* 1984;16:157-168.
4. Hardebo JE. The involvement of trigeminal substance P neurons in cluster headache. An hypothesis. *Headache* 1984;24:294-304.
5. Lembeck F, Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. *Naunyn Schmiedebergs Arch Pharmacol* 1979; 210:175-183.
6. Saria A, Gamse R, Lundberg JM, et al. Coexistence of tachykinins and calcitonin gene-related peptide in sensory nerves in relation to neurogenic inflammation. In: Håkanson R, Sundler F, eds. Tachykinin antagonists. New York: Elsevier Science Publishing, 1985.
7. Saria A, Gamse R, Petermann J, et al. Simultaneous release of several tachykinins and calcitonin gene-related peptide from rat spinal cord slices. *Neurosci Lett* 1986;63:310-314.
8. Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-related peptide is a potent vasodilator. *Nature* 1985;313:54-56.
9. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. *J Neurosci* 1987;7:4129-4136.
10. Ray BS, Wolff HG. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. *Arch Surg* 1940;41:813-856.
11. Andres KH, von Düring M, Muszynski K, et al. Nerve fibres and their

- Anat Embryol (Berl) 1987;175:289-301.
12. Steiger HJ, Tew JM Jr, Keller JT. The sensory representation of the dura mater in the trigeminal ganglion of the cat. *Neurosci Lett* 1982;31:231-236.
13. Mayberg MR, Zervas NT, Moskowitz MA. Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. *J Comp Neurol* 1984;223:46-56.
14. Dimitriadou V, Buzzi MG, Moskowitz MA, et al. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. *Neuroscience* 1991;44:97-112.
15. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. *Br J Pharmacol* 1990;99:202-206.
16. Moskowitz MA. The visceral organ brain: implications for the pathophysiology of vascular head pain. *Neurology* 1991; 41:182-186.
17. Lembeck F. Sir Thomas Lewis's nocifensor system, histamine and substance-P-containing primary afferent nerves. *TINS* 1983;6:106-108.
18. Saria A, Lundberg JM, Skofitsch G, et al. Vascular protein leakage in various tissues induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge. *Naunyn Schmiedebergs Arch Pharmacol* 1983; 324:212-218.
19. Levine JD, Clark R, Devor M, et al. Intraneuronal substance P contributes to the severity of experimental arthritis. *Science* 1984;226:547-568.
20. Fields HL. Pain. New York: McGraw-Hill Book Co, 1987:13-40.
21. Buzzi MG, Moskowitz MA, Peroutka SJ, et al. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. *Br J Pharmacol* 1991;103:1421-1428.
22. Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT₁-like receptor agonist, for the acute treatment of severe migraine. *Lancet* 1988;1:1309-1311.
23. Buzzi MG, Carter WB, Shimizu T, et al. Dihydroergotamine and sumatriptan attenuate the levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. *Neuropharmacology* 1991;30:1193-1200.
24. Buzzi MG, Dimitriadou V, Theoharides T, et al. 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial, and platelet activation within the rat dura mater after trigeminal stimulation. *Brain Res* 1992;583:137-149.
25. Bruinvels AT, Landwehrmeyer B, Moskowitz MA, et al. Evidence for presence of 5-HT_{1B} receptor messenger RNA in neurons of the rat trigeminal ganglia. *Eur J Pharmacol* 1992;227:357-359.
26. Sleight AJ, Cervenka A, Peroutka SJ. In vivo effects of sumatriptan (GR43175) on extracellular levels of 5-HT in guinea pig. *Neuropharmacology* 1990;29:511-513.
27. Matsubara T, Moskowitz MA, Huang Z. UK-14, 304, R(-)- α -methyl-histamine and octreotide (SMS201-995) block plasma protein within dura mater by prejunctional mechanisms. *Eur J Pharmacol* 1992;224:145-150.
28. Morgan JI, Curran T. Stimulus-transcription coupling in neurons: role of cellular immediate-early genes. *TINS* 1989;12(11):459-462.
29. Sambucetti LC, Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. *Science* 1988;240:1328-1331.
30. Sheng M, Greenberg ME. The regulation and function of c-fos and other immediate early genes in the nervous system. *Neuron* 1990;4:477-485.
31. Curran T, Morgan JI. Superinduction of c-fos by nerve growth factor in the presence of peripherally active benzodiazepines. *Science* 1985;229:1265-1268.
32. Hunt SP, Pini A, Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. *Nature* 1987;328:632-634.

- activity in rat brainstem neurons following noxious chemical stimulation of the nasal mucosa. *Neuroscience* 1991; 41:629-641.
34. Bullitt E. Expression of *c-fos*-like protein as a marker for neuronal activity following noxious stimulation in the rat. *J Comp Neurol* 1990;296:517-530.
 35. Presley RW, Menétrey D, Levine JD, et al. Systemic morphine suppresses noxious stimulus-evoked fos protein-like immunoreactivity in the rat spinal cord. *J Neurosci* 1990; 10:323-335.
 36. Gogas KR, Presley RW, Levine JD, et al. The antinociceptive action of supraspinal opioids results from an increase in descending inhibitory control: correlation of nociceptive behavior and *c-fos* expression. *Neuroscience* 1991;42:617-628.
 37. Nozaki K, Boccalini P, Moskowitz MA. Expression of *c-fos*-like immunoreactivity in brain stem after meningeal irritation by blood in the subarachnoid space. *Neuroscience* 1992;49:669-680.
 38. Strassman A, Mason P, Moskowitz M, et al. Response of brainstem trigeminal neurons to electrical stimulation of the dura. *Brain Res* 1986;379:242-250.
 39. Macor JE, Bukhart JH, Heym JH, et al. 3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-*b*]pyrid-5-one: a potent and selective serotonin (5-HT_{1B}) agonist and rotationally restricted phenolic analogue of 5-methyl-3-(1,2,5,6-tetrahydropyrid-4-yl)indole. *J Med Chem* 1990;33:1087-1093.
 40. Matsubara T, Moskowitz MA, Byun B. CP-93,129, a potent and selective 5-HT_{1B}-receptor agonist blocks neurogenic plasma extravasation within rat but not guinea-pig dura mater [special report]. *Br J Pharmacol* 1991;104:3-4.
 41. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block *c-fos* expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. *Br J Pharmacol* 1992;106:409-415.
 42. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of *c-fos* protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. *J Neurosci* 1993;13:1167-1177.
 43. Moskowitz MA. Neurogenic vs vascular mechanisms of sumatriptan and ergot alkaloids in migraine. *Trends Pharmacol Sci* 1992;13:307-311.

Cen

K.M.A. V

Article abstract
spectroscopy indic
and ³¹P magnetic
in migraine suffer
threshold for migr

A process of ex
neurons can exp
sive characteris
migraine aura a
known neural p
sion (SD) descr
the most likely
picture of mig
unique magnet
ral events that
sented to supp
evidence for SD w
vivo ³¹P magne
Findings from
that patients v
are susceptible
magnesium (Mg

Neurophysiol
Enhanced cent
tibility to spont
considered cha
Subsequent ne
sion of neuron
observations, h
depression cons
followed by a s
spreads slowl
Leão¹ speculat
to migraine a
Lashley² made
that preceded l
culated that tl
in the occipital
3 mm/min. M

From the Departmen
Address corresponde
Grand Boulevard, De

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.